Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus sacituzumab tirumotecan as neoadjuvant bladder-preserving therapy for muscle-invasive bladder cancer
ChiCTR2600119425Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and sacituzumab tirumotecan in muscle-invasive bladder carcinoma (MIBC), sponsored by Tangdu Hospital. Primary endpoint: clinical complete response rate. Started Feb 2026; status: recruiting.
02
Drugs
adebrelimabsacituzumab tirumotecan
03
Conditions
muscle-invasive bladder carcinoma (MIBC)
Beyond the preview
Go deeper on ChiCTR2600119425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119425.